- Home
- NML vs VALN Comparison
NML vs VALN Comparison
Compare NML & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NML
- VALN
- Stock Information
- Founded
- NML 2012
- VALN 2012
- Country
- NML United States
- VALN France
- Employees
- NML N/A
- VALN N/A
- Industry
- NML Finance/Investors Services
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NML Finance
- VALN Health Care
- Exchange
- NML Nasdaq
- VALN Nasdaq
- Market Cap
- NML 454.4M
- VALN 510.7M
- IPO Year
- NML N/A
- VALN 2021
- Fundamental
- Price
- NML $8.38
- VALN $6.38
- Analyst Decision
- NML
- VALN Strong Buy
- Analyst Count
- NML 0
- VALN 3
- Target Price
- NML N/A
- VALN $15.33
- AVG Volume (30 Days)
- NML 219.3K
- VALN 15.0K
- Earning Date
- NML 01-01-0001
- VALN 05-07-2025
- Dividend Yield
- NML 9.75%
- VALN N/A
- EPS Growth
- NML N/A
- VALN N/A
- EPS
- NML N/A
- VALN N/A
- Revenue
- NML N/A
- VALN $201,099,222.00
- Revenue This Year
- NML N/A
- VALN $17.98
- Revenue Next Year
- NML N/A
- VALN $26.61
- P/E Ratio
- NML N/A
- VALN N/A
- Revenue Growth
- NML N/A
- VALN 21.64
- 52 Week Low
- NML $6.09
- VALN $3.62
- 52 Week High
- NML $7.33
- VALN $9.50
- Technical
- Relative Strength Index (RSI)
- NML 49.52
- VALN 44.94
- Support Level
- NML $8.20
- VALN $6.25
- Resistance Level
- NML $8.54
- VALN $6.65
- Average True Range (ATR)
- NML 0.22
- VALN 0.32
- MACD
- NML 0.03
- VALN -0.02
- Stochastic Oscillator
- NML 64.79
- VALN 20.35
About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.